Technological Offers

BRITE-A: Precision medicine for the treatment of obesity.

Description


A nanosystem consisting of a gold nanoparticle + surfactant + miRNA that acts as an anti-obesity drug and a nanosystem targeting system that allows its specific capture by adipose tissue (AT) in localized areas.

The miRNA acts on the white AT (energy storage) transforming it into beige AT (with thermogenic activity) while activating thermogenesis in both beige and brown AT (thermogenic activity).

Medical need

Obesity is considered the pandemic of the 21st century by the World Health Organization. It is characterized by a high BMI (>30) and is one of the main risk factors for other diseases such as diabetes, cancer, cardiovascular and musculoskeletal diseases.

However, the availability of treatments and their efficacy is limited, with decreased caloric intake and increased exercise currently being the most widespread therapy.

Prevalence

In 2022, 16% of adults worldwide were obese.

Market

Obesity treatment:

In 2022: $15 billion.

Expected 2032: $38 billion.

Expected CAGR of 10.0%.

Other solutions

Orlistat: Reduction of fat absorption.

Liraglutide: GLP-1 agonist

Bupropion/ Naltrexona: Increased energy expenditure.

Results

The nanosystem and the targeting system have been validated in an animal model of obesity, obtaining, among others, evidence of:

  • Decreased weight gain in animals fed a high-fat diet.
  • Overexpression of miRNA in tissue.
  • Overexpression of the thermogenesis pathway.

Therapy


IBIMA Plataforma BIONAND inventors


RAJAA EL BEKAY RIZKY
Research group of IBIMA involved: A-01

FRANCISCO JOSÉ TINAHONES MADUEÑO
Research group of IBIMA involved: A-02

Contact


Innovation and Technology Transfer Office of IBIMA Plataforma BIONAND

transferencia@ibima.eu